window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : February 10, 2026

  • News
  • About Us
Contact Us

DEBRA Research

  • Biotech,Clinical Development,Clinical studies,Rare Diseases,Research & Development

    DEBRA Research and University Medical Center Groningen launch dedicated clinical trial site for Epidermolysis Bullosa

    DEBRA Research and the University Medical Center Groningen (UMCG) have [...]

    January 19, 2026
  • Biologics & Biosimilars,Biotech,Partnerships & Funding,Rare Diseases,Research & Development

    DEBRA Research and Nonsense Therapeutics launch ReadOn Therapeutics to target epidermolysis bullosa

    DEBRA Research gGmbH, a global non-profit dedicated to advancing research [...]

    September 26, 2025
  • Drug Development,Partnerships & Funding,Rare Diseases,Research & Development

    DEBRA Research and Queen Mary University of London partner to advance drug development for rare skin disorder

    DEBRA Research, a non-profit focused on Epidermolysis bullosa (EB), has [...]

    August 7, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SpotitEarly partners with Fox Chase Cancer Center to advance breath-based cancer detection trials
    Categories: Artificial Intelligence, Clinical Trials, Diagnostics, Oncology
  • DFE Pharma launches EcoLact 2030 to cut CO₂ emissions across lactose excipients
    Categories: Ingredients, Manufacturing, Pharmaceuticals and therapeutics, Sustainability
  • Cereno Scientific broadens CS014 development focus to pulmonary hypertension linked to interstitial lung disease
    Categories: Clinical Development, Clinical Trials, Rare Diseases, Respiratory
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top